Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, that enhance immune killing of tumor
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala...
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019...
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the...